Enthusiasm for development of the anti-CD40 ligand monoclonal antibody is "undiminished" despite the company's decision to suspend Phase II clinical trials late in 1999 due to reports of thromboembolic adverse events, Biogen President James Mullen told Chase H&Q ("The Pink Sheet" Nov. 8, 1999, p. 26). "We are currently in the process of determining whether these events are related to the drug itself, to other ingredients in the formulation, or to the underlying disease of the patients involved," Mullen said
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth